James B. Kahn, M.D., FIDSA is the founder and principal of JBK Strategic Consultations, LLC, a small firm providing Infectious Disease expertise to the Pharmaceutical, Venture Capital, and Medico-legal communities.
He was graduated from Harvard College with a B.A. magna cum laude in Latin American History and Literature and obtained his M.D. degree with honors from Harvard Medical School. After performing an Internal Medicine internship and junior residency at Boston’s Beth Israel Hospital, he served for two years at CDC as an EIS officer with the rank of Lieutenant Commander (Major). He returned to Boston for a year’s senior residency in Internal Medicine at the Beth Israel, then took a two year clinical Infectious Diseases fellowship at the Massachusetts General Hospital. He is Board-certified in both I.M. and I.D..
After 18 years in the solo private practice of I.D. Medicine, during the course of which he founded and was president of the Northern New England Infectious Diseases Society, Dr. Kahn was recruited by Johnson & Johnson’s Ortho-McNeil Pharmaceutical to be the first Director of their new I.D. Franchise. In addition to doing numerous clinical trials for the antimicrobial FLOXIN, he also took over the clinical development of LEVAQUIN and was responsible for the sNDAs that led to 8 new FDA-approved indications. He proposed and then developed the higher-dose, shorter-course approach to accelerate pathogen eradication and reduce anti-bacterial exposure. At the time of his retirement after more than 15 years at J&J, he had authored more than 140 peer-reviewed scientific papers and presentations at major Infectious Disease meetings.
He has been offering his consulting services since leaving Industry in 2007 and continues professional society membership in ASM, IDSA, ESCMID, NNEIDS, RSTMH, and ISID. He attends numerous national and international I.D. meetings and maintains close personal and profession contacts with many US and global opinion leaders.